½ÃÀ庸°í¼­
»óǰÄÚµå
1741275

¼¼°èÀÇ Æä³ë¹Ù¸£ºñÅ»(Phenobarbital) ½ÃÀå : ÀûÀÀÁõº°, Á¦Çüº°, À¯Åë ä³Îº°, Áö¿ªº°

Phenobarbital Market, By Indication, By Dosage Form, By Distribution Channel, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Æä³ë¹Ù¸£ºñÅ» ½ÃÀåÀº 2025³â¿¡´Â 17¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2032³â¿¡´Â 24¾ï 5,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â¿¡ °ÉÃÄ CAGR 5%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎ Á¤º¸
±âÁØ ¿¬µµ 2024³â ½ÃÀå ±Ô¸ð(2025³â) 17¾ï 4,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
CAGR(2025-2032³â) 5.00% 2032³â ±Ý¾× ¿¹Ãø 24¾ï 5,000¸¸ ´Þ·¯

Æä³ë¹Ù¸£ºñÅ»Àº ¹ßÀÛÀ» Ä¡·áÇϰųª ¿¹¹æÇϱâ À§ÇØ »ç¿ëµÇ´Â ¾à¹°ÀÔ´Ï´Ù. ÀÌ ¾à¹°Àº ¹ßÀÛÀ» ÀÏÀ¸Å°´Â ³úÀÇ ºñÁ¤»óÀûÀÎ Àü±â Ȱµ¿À» Á¶ÀýÇÔÀ¸·Î½á ÀÛ¿ëÇÕ´Ï´Ù. ÀÌ ¾à¹°Àº Ç×°æ·ÃÁ¦ ¹× ÁøÁ¤Á¦¶ó´Â ¾à¹° ºÐ·ù¿¡ ¼ÓÇÕ´Ï´Ù. ¶ÇÇÑ ºÒ¾ÈÇϰųª ±äÀåµÈ »óÅ¿¡¼­ »ç¶÷ÀÌ À̿ϵǰųª Àáµéµµ·Ï µ½±â À§ÇØ »ç¿ëµÇ±âµµ ÇÕ´Ï´Ù. ÀÌ ¾à¹°Àº ÀÇ»çÀÇ Ã³¹æÀÌ ÀÖ¾î¾ß¸¸ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ ¾à¹°À» Àå±â°£ »ç¿ë ½Ã À§ÇèÀÌ ÀÖÀ» ¼ö ÀÖ½À´Ï´Ù. À̴ ƯÁ¤ ¿µ¾ç¼Ò(Ä®½·, ºñŸ¹Î B, ¿±»ê, ºñŸ¹Î D)ÀÇ Èí¼ö³ª ´ë»ç Àå¾Ö¸¦ Æ÷ÇÔÇÕ´Ï´Ù. ¶ÇÇÑ ÀÎü¿¡¼­ Á¤»óÀûÀÎ ¼¼Æ÷ ±â´É¿¡ Áß¿äÇÑ ÀüÇØÁúÀÎ Àλ꿰ÀÇ Ç÷Áß ³óµµ¸¦ ³·Ãâ ¼ö ÀÖ½À´Ï´Ù. Àå±â°£ »ç¿ë ½Ã °©»ó¼± È£¸£¸ó Àå¾Ö¸¦ À¯¹ßÇÒ ¼öµµ ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

Æä³ë¹Ù¸£ºñÅ»Àº °£Áú ¹× ¹ßÀÛ Àå¾Ö °ü¸®¿¡ È¿°úÀûÀ̶ó´Â Á¡¿¡¼­ Àß ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ƯÈ÷ ÀÚ¿øÀÌ ºÎÁ·ÇÑ Áö¿ª¿¡¼­ ¿©·¯ À¯ÇüÀÇ ¹ßÀÛ¿¡ ´ëÇÑ Ã¹ ¹øÂ° Ä¡·áÁ¦·Î ÀÎÁ¤¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ ¾à¹°ÀÇ ¹ßÀÛÀ» È¿°úÀûÀ¸·Î ¾ïÁ¦ÇÏ´Â ´É·ÂÀº ½ÃÀå¿¡¼­ÀÇ ¼ö¿ä¿Í »ç¿ëÀ» ÃËÁøÇÕ´Ï´Ù.

Æä³ë¹Ù¸£ºñÅ» ½ÃÀåÀº ¾ÈÀü¼º ÇÁ·ÎÆÄÀϰú ºÎÀÛ¿ëÀÌ ÀûÀº ´ëü Ç×°æ·ÃÁ¦ÀÇ °ø±Þ ºÎÁ·À¸·Î ÀÎÇØ Á¦¾àÀ» ¹Þ°í ÀÖ½À´Ï´Ù. »õ·Î¿î ¾à¹°ÀÇ °³¹ß·Î ÀÎÇØ ´Ù¾çÇÑ ÀÛ¿ë ¸ÞÄ¿´ÏÁò°ú ƯÁ¤ ÀûÀÀÁõÀ» °¡Áø Ãß°¡ÀûÀÎ ´ëü Ä¡·á ¿É¼ÇÀÌ µîÀåÇß½À´Ï´Ù. ƯÈ÷ ºÎÀÛ¿ëÀ̳ª ¾à¹° »óÈ£ÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇØ¾ß ÇÏ´Â °æ¿ì ÀÇ·áÁøÀº Æä³ë¹Ù¸£ºñÅ» ´ë½Å ÀÌ·¯ÇÑ ½Å±Ô ¾à¹°À» ó¹æÇÒ ¼ö ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ Æä³ë¹Ù¸£ºñÅ» ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ ¿¬µµÀ¸·Î ÇÑ ¿¹Ãø±â°£ 2025-2032³â ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR%)À» Á¦°øÇÕ´Ï´Ù.
  • ¶Ç, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¼³¸íÇϰí, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¿¡ ´ëÇØ¼­ ÇØ¼³Çß½À´Ï´Ù.
  • ¶Ç ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç°ÀÇ Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ª¿¡ ÀÇÇÑ Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ °íÂûµµ Á¦°øÇÕ´Ï´Ù.
  • ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅÍ¿¡ ±Ù°ÅÇØ, ¼¼°èÀÇ Æä³ë¹Ù¸£ºñÅ» ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀÏ Çϰí ÀÖ½À´Ï´Ù.
  • ÀÌ º¸°í¼­·ÎºÎÅÍ ÅëÂû¿¡ ÀÇÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ³ª ±â¾÷ÀÇ °æ¿µÁøÀº Àå·¡ÀÇ Á¦Ç°ÀÇ ¹ß¸Å, Àåºñ ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ °üÇÑ Á¤º¸¿¡ ±Ù°ÅÇÑ ÀÇ»ç °áÁ¤À» ½Ç½ÃÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°èÀÇ Æä³ë¹Ù¸£ºñÅ» ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±ÞÀÚ, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ °ü°èÀÚ¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚ´Â ¼¼°èÀÇ Æä³ë¹Ù¸£ºñÅ» ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû ¹× ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • ÀϰüµÈ ±âȸ Áöµµ(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
  • °£Áú ¹ß»ý·ü Áõ°¡
    • ¾ïÁ¦¿äÀÎ
  • ´ëü Ç×°£Áú ¾à¹°ÀÇ °¡¿ë¼º
  • ºÎÀÛ¿ë ¹× ¾ÈÀü¼º ¹®Á¦
    • ±âȸ
  • ½Å»ý¾Æ ¹ßÀÛ ¹ß»ý·ü Áõ°¡
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¦Ç° Ãâ½Ã ¹× ½ÂÀÎ
  • PEST ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ÇÕº´, Àμö, Á¦ÈÞ

Á¦4Àå ¼¼°èÀÇ Æä³ë¹Ù¸£ºñÅ» ½ÃÀå : Äڷγª ¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • COVID-19 ¿ªÇÐ
  • °ø±Þ Ãø¸é ¹× ¼ö¿ä Ãø¸é ºÐ¼®
  • °æÁ¦¿¡ ¹ÌÄ¡´Â ¿µÇâ

Á¦5Àå ¼¼°èÀÇ Æä³ë¹Ù¸£ºñÅ» ½ÃÀå : ÀûÀÀÁõº°(2020-2032³â)

  • ¼Ò°³
  • °£Áú
  • ½Å»ý¾Æ ¹ßÀÛ

Á¦6Àå ¼¼°èÀÇ Æä³ë¹Ù¸£ºñÅ» ½ÃÀå : Á¦Çüº°(2020-2032³â)

  • ¼Ò°³
  • Á¤Á¦
  • ĸ½¶
  • ÁÖ»çÁ¦

Á¦7Àå ¼¼°èÀÇ Æä³ë¹Ù¸£ºñÅ» ½ÃÀå : À¯Åë ä³Îº°(2020-2032³â)

  • ¼Ò°³
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦8Àå ¼¼°èÀÇ Æä³ë¹Ù¸£ºñÅ» ½ÃÀå : Áö¿ªº°(2020-2032³â)

  • ¼Ò°³
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ½ºÆäÀÎ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Àεµ
    • Áß±¹
    • ÀϺ»
    • È£ÁÖ
    • ASEAN ±¹°¡
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿
    • GCC ±¹°¡
    • À̽º¶ó¿¤
    • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
    • ºÏ¾ÆÇÁ¸®Ä«
    • Áß¾Ó ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï ±¸µµ

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Sanofi
    • Pfizer Inc
    • Novartis AG.
    • Lundbeck A/S
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Hikma Pharmaceuticals
    • Cipla Ltd.
    • Par Pharmaceutical
    • Analysts'Views

Á¦10Àå ¼½¼Ç

  • Âü°í¹®Çå
  • Á¶»ç ¹æ¹ý
  • ȸ»ç ¼Ò°³
HBR

Phenobarbital Market is estimated to be valued at USD 1.74 Bn in 2025 and is expected to reach USD 2.45 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 1.74 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 5.00% 2032 Value Projection: USD 2.45 Bn

Phenobarbital is a medicine which is used to treat or prevent seizures. It works by regulating the abnormal electrical activity in the brain that causes seizures. It is a class of medications called anticonvulsants and sedatives. It is also sometimes used for to help a person relax or sleep when he/she is anxious or nervous. This medication is available only with a doctor's prescription.

There is risk associated with the use of this medication if it is used for a long time. These include problems with how the body uses or absorbs certain nutrients (e.g., calcium, B vitamins, folic acid, and vitamin D). It can also lower the blood levels of phosphate, an electrolyte that is important for normal cell function. Long-term use of this medication can also cause problems with thyroid hormones.

Market Dynamics

Phenobarbital is well-known for its effectiveness in the management of epilepsy and seizure disorders. It is regarded as a first-line treatment for several types of seizures, especially in areas with limited resources. The drug's ability to effectively stop seizures fuels demand for and use of it on the market.

The market for phenobarbital is constrained by the availability of substitute anti-epileptic medications with enhanced safety profiles and fewer adverse effects. There are additional alternatives for treating epilepsy and seizure disorders which is due to the development of new drugs with various mechanisms of action and focused indications. Especially, in situations when limiting adverse effects or drug interactions is important, healthcare practitioners may choose to prescribe these newer medications over phenobarbital.

Key features of the study:

  • This report provides an in-depth analysis of the global phenobarbital market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global phenobarbital market based on the following parameters - company highlights, product portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Sanofi, Pfizer Inc., Novartis AG, H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals, Cipla Ltd., and Par Pharmaceutical
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global phenobarbital market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global phenobarbital market

Global Phenobarbital Market Detailed Segmentation:

  • By Indication
    • Epilepsy
    • Neonatal Seizures
  • By Dosage Form
    • Tablets
    • Capsules
    • Injectables
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Company Profiles
    • Sanofi
    • Pfizer Inc.
    • Novartis AG
    • Lundbeck A/S
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Hikma Pharmaceuticals
    • Cipla Ltd.
    • Par Pharmaceutical

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Indication
    • Market Snippet, By Dosage Form
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
  • Increasing prevalence of epilepsy
    • Restraints
  • Availability of alternative anti-epileptic Drugs
  • Adverse effects and safety concerns
    • Opportunities
  • Increasing prevalence of neonatal seizures
  • Key Highlights
  • Regulatory Scenario
  • Recent Trends
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Mergers, Acquisitions and Collaborations

4. Global Phenobarbital Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Phenobarbital Market, By Indication, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Epilepsy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
  • Neonatal Seizures
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)

6. Global Phenobarbital Market, By Dosage Form, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Tablets
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
  • Capsules
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
  • Injectables
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)

7. Global Phenobarbital Market, By Distribution Channel, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)

8. Global Phenobarbital Market, By Region, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Country, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Country 2021 -2032
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020 - 2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
      • U.S.
      • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020 - 2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020 - 2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
      • India
      • China
      • Japan
      • Australia
      • ASEAN
      • South Korea
      • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020 - 2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020 - 2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032 (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020 - 2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032 (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Bn)
      • North Africa
      • Central Africa
      • South Africa

9. Competitive Landscape

  • Company Profiles
    • Sanofi
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Pfizer Inc
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Novartis AG.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Lundbeck A/S
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Teva Pharmaceutical Industries Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Sun Pharmaceutical Industries Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Hikma Pharmaceuticals
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Cipla Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Par Pharmaceutical
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Analysts' Views

10. Section

  • References
  • Research Methodology
  • About us
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦